Integrated safety analysis of umbralisib, a dual PI3Kd/CK1« inhibitor, in relapsed/refractory lymphoid malignancies

Phosphoinositide 3-kinase-d (PI3Kd) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kd and casein kinase-1« (CK1«). This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1 and 2 studies that included 371 adult patients (median age, 67 years) with relapsed/refractory non-Hodgkin lymphoma (follicular lymphoma [n 5 147]; marginal zone lymphoma [n 5 82]; diffuse large B-cell lymphoma/mantle cell lymphoma [n 5 74]; chronic lymphocytic leukemia [n 5 43]; and other tumor types [n 5 25]) who were treated with the recommended phase 2 dose of umbralisib 800 mg or higher once daily. At data cutoff, median duration of umbralisib treatment was 5.9 months (range, 0.1-75.1 months), and 107 patients (28.8%) received umbralisib for $12 months. Any-grade treatment-emergent adverse events (AEs) occurred in 366 (98.7%) of 371 patients, with the most frequent being diarrhea (52.3%), nausea (41.5%), and fatigue (31.8%). Grade 3 or higher treatment-emergent AEs occurred in 189 (50.9%) of 371 patients and included neutropenia (11.3%), diarrhea (7.3%), and increased aminotransferase levels (5.7%). Treatment-emergent serious AEs occurred in 95 (25.6%) of 371 patients. AEs of special interest were limited and included pneumonia (29 of 371 [7.8%]), noninfectious colitis (9 of 371 [2.4%]), and pneumonitis (4 of 371 [1.1%]). AEs led to discontinuation of umbralisib in 51 patients (13.7%). Four patients (1.1%) died of AEs, none of which was deemed related to umbralisib. No cumulative toxicities were reported. The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Purpose: In the phase 3 DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated significantly improved efficacy vs ofatumumab (median [m]PFS, 13.3 vs 9.9 months [HR, 0.52; P < .0001]; ORR, 74% vs 45% [P < .0001]), with a manageable safety profile in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). We report results from patients with progressive disease (PD) after ofatumumab who crossed over to duvelisib in the DUO trial. Experimental Design: Patients with radiographically confirmed PD after ofatumumab received duvelisib 25 mg twice daily in 28-day cycles until PD, intolerance, death, or study withdrawal. The primary endpoint was ORR per investigator. Secondary endpoints included duration of response (DOR), PFS, and safety. Results: As of December 14, 2018, 90 ofatumumab-treated patients in the DUO trial prior to crossover had an ORR of 29%, mDOR of 10.4 months, and mPFS of 9.4 months. After crossover, 77% of patients (69/90) achieved a response, with an mDOR of 14.9 months and mPFS of 15.7 months. Patients with del(17p) and/or TP53 mutations had similar outcomes (ORR, 77% [20/26]; mPFS, 14.7 months). Notably, 73% of patients (47/64) with disease previously refractory to ofatumumab achieved a response. The most frequent any-grade/grade 3/4 treatment-emergent adverse events were diarrhea (47%/23%), neutropenia (26%/23%), pyrexia (24%/4%), cutaneous reactions (23%/4%), and thrombocytopenia (10%/6%). Conclusions: Duvelisib demonstrated high response rates with good durability and a manageable safety profile in patients with R/R CLL/SLL who progressed on ofatumumab, including patients with high-risk disease and disease previously refractory to ofatumumab

A frequency-optimised temperature record for the Holocene

Existing global mean surface temperature reconstructions for the Holocene lack high-frequency variability that is essential for contextualising recent trends and extremes in the Earth’s climate system. Here, we isolate and recombine archive-specific climate signals to generate a frequency-optimised record of interannual to multi-millennial temperature changes for the past 12 000 years. Average temperatures before ∼8000 years BP and after ∼4000 years BP were 0.26 (±2.84) °C and 0.07 (±2.11) °C cooler than the long-term mean (0–12 000 years BP), while the Holocene Climate Optimum ∼7000–4000 years BP was 0.40 (±1.86) °C warmer. Biased towards Northern Hemisphere summer temperatures, our multi-proxy record captures the spectral properties of transient Earth system model simulations for the same spatial and season domain. The new frequency-optimised trajectory emphasises the importance and complex interplay of natural climate forcing factors throughout the Holocene, with an approximation of the full range of past temperature changes providing novel insights for policymakers addressing the risks of recent anthropogenic warming

A frequency-optimised temperature record for the Holocene

Existing global mean surface temperature reconstructions for the Holocene lack high-frequency variability that is essential for contextualising recent trends and extremes in the Earth's climate system. Here, we isolate and recombine archive-specific climate signals to generate a frequency-optimised record of interannual to multi-millennial temperature changes for the past 12 000 years. Average temperatures before ∼8000 years BP and after ∼4000 years BP were 0.26 (±2.84) • C and 0.07 (±2.11) • C cooler than the long-term mean (0-12 000 years BP), while the Holocene Climate Optimum ∼7000-4000 years BP was 0.40 (±1.86) • C warmer. Biased towards Northern Hemisphere summer temperatures, our multi-proxy record captures the spectral properties of transient Earth system model simulations for the same spatial and season domain. The new frequency-optimised trajectory emphasises the importance and complex interplay of natural climate forcing factors throughout the Holocene, with an approximation of the full range of past temperature changes providing novel insights for policymakers addressing the risks of recent anthropogenic warming